MyPennGenome (MPG)
MyPennGenome (MPG) is a translational research program to evaluate preventive whole genome sequencing as a scalable, equitable, and medically effective strategy for disease interception in healthy adults.
By returning medically actionable genomic results through an integrated healthcare workflow, MPG seeks to determine whether genome sequencing can enable earlier prevention, surveillance, diagnosis, and treatment before disease symptoms emerge. MPG builds on extensive evidence from basic science research, precision health initiatives, and genomic screening efforts that have shown that genome sequencing can identify medically actionable findings in generally healthy individuals. MPG aims to rigorously evaluate whether genomic information, when embedded into coordinated clinical care, can improve health outcomes for individuals and their families.
MPG vision is to transform preventive whole genomic sequencing into an actionable health-system platform for disease interception.
Leveraging Penn’s world-class research innovation, clinical expertise, and leading healthcare system, MPG will create and evaluate an end-to-end model for genomic screening that spans consent, CLIA-grade sequencing, AI-enabled genome interpretation, clinical reporting, genetic counseling, primary-care engagement, specialty referral, and longitudinal follow-up. MPG aims to establish a new paradigm in preventive care: one in which genomic risk is not simply disclosed, but translated into timely, evidence-based action. By embedding medically actionable findings into coordinated workflows, MPG will test whether preventive genomic sequencing can trigger earlier surveillance, risk reduction, pharmacogenomic optimization, family cascade testing, and targeted clinical intervention.
Research hypothesis: Preventive genomic sequencing, incorporating CLIA-grade sequencing and cutting-edge artificial intelligence algorithms for genome interpretation, can serve as a disease-interception platform when medically actionable findings are embedded into coordinated medical workflows that trigger timely prevention, surveillance, and treatment for individuals and their families.
MPG is a key partnership of the Center for Computational Biomedicine (CCB), the Genetic Diagnosis Laboratory (GDL) and the Penn Medicine BioBank (PMBB) at Penn Medicine.
